Figure 6.

Targeting 16E5 to DCs together with anti-PD-1 immunotherapy improves the immune response against the tumor. (A) Mice immunization was performed as indicated in Figure 2 with anti-DEC-205:16E5 or PBS, using the therapeutic model. Mice that developed tumors (30%) after vaccination with the anti-DEC-205:16E5 conjugate (anti-DEC-205:16E5T), were inoculated i.p. with the anti-PD-1 mAb or the mAb III-10 as isotype control on the indicated days. Tumor growth (left panel) and mice survival (right panel) were followed for up to 100 days. Data from one experiment with five mice per group is shown. (B) Seventy-two and 92 days after tumor cell inoculation, TILs were obtained and stained with different mAbs coupled to fluorochromes and analyzed by flow cytometry. The percentages of CD4⁺ and CD8⁺ (left panel) and of CD4⁺ PD-1⁺ and CD8⁺ PD-1⁺ (right panel) T cells are shown. Data from one experiment with three mice per group is shown. Vertical bars indicate standard deviation. Statistically significant differences are represented as p values (*< 0.05).